Recent advances and developments in COVID‐19 in the context of allergic diseases

Background Since the first reports of coronavirus disease 2019 (COVID‐19) in Wuhan, China, in December 2019, there have been 198 million confirmed cases worldwide as of August 2021. The scientific community has joined efforts to gain knowledge of the newly emerged virus named severe acute respirator...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and translational allergy Vol. 11; no. 7; pp. e12065 - n/a
Main Authors: Ding, Mei, Dong, Xiang, Sun, Yuan‐li, Sokolowska, Milena, Akdis, Mübeccel, Veen, Willem, Azkur, Ahmet Kursat, Azkur, Dilek, Akdis, Cezmi A., Gao, Ya‐dong
Format: Journal Article
Language:English
Published: England John Wiley & Sons, Inc 01.09.2021
John Wiley and Sons Inc
Wiley
Subjects:
Allergies
allergy
Asthma
Biomarkers
Clinical outcomes
Coronaviruses
COVID-19
Cytokines
Disease
Gene expression
Genotype & phenotype
Hay fever
Immunotherapy
Impfung
Infections
Inflammation
mechanism
Mechanismen
Medical supplies
Mortality
Pandemics
Proteins
Review
Rhinitis
Schlüsselwörter: Allergie
Severe acute respiratory syndrome coronavirus 2
Therapie
treatment
vaccination
Viral infections
Viruses
United Kingdom > UK
COVID-19
Mechanismen
treatment
Therapie
Impfung
Schlüsselwörter: Allergie
allergy
mechanism
vaccination
ISSN:2045-7022, 2045-7022
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Background Since the first reports of coronavirus disease 2019 (COVID‐19) in Wuhan, China, in December 2019, there have been 198 million confirmed cases worldwide as of August 2021. The scientific community has joined efforts to gain knowledge of the newly emerged virus named severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the immunopathological mechanisms leading to COVID‐19, and its significance for patients with allergies and asthma. Methods Based on the current literature, recent advances and developments in COVID‐19 in the context of allergic diseases were reviewed. Results and Conclusions In this review, we discuss the prevalence of COVID‐19 in subjects with asthma, attacks of hereditary angioedema, and other allergic diseases during COVID‐19. Underlying mechanisms suggest a protective role of allergy in COVID‐19, involving eosinophilia, SARS‐CoV‐2 receptors expression, interferon responses, and other immunological events, but further studies are needed to fully understand those associations. There has been significant progress in disease evaluation and management of COVID‐19, and allergy care should continue during the COVID‐19 pandemic. The European Academy of Allergy & Clinical Immunology (EAACI) launched a series of statements and position papers providing recommendations on the organization of the allergy clinic, handling of allergen immunotherapy, asthma, drug hypersensitivity, allergic rhinitis, and other allergic diseases. Treatment of allergies using biologics during the COVID‐19 pandemic has also been discussed. Allergic reactions to the COVID‐19 vaccines, including severe anaphylaxis, have been reported. Vaccination is a prophylactic strategy that can lead to a significant reduction in the mortality and morbidity associated with SARS‐CoV‐2 infection, and in this review, we discuss the proposed culprit components causing rare adverse reactions and recommendations to mitigate the risk of anaphylactic events during the administration of the vaccines.
AbstractList Background Since the first reports of coronavirus disease 2019 (COVID‐19) in Wuhan, China, in December 2019, there have been 198 million confirmed cases worldwide as of August 2021. The scientific community has joined efforts to gain knowledge of the newly emerged virus named severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the immunopathological mechanisms leading to COVID‐19, and its significance for patients with allergies and asthma. Methods Based on the current literature, recent advances and developments in COVID‐19 in the context of allergic diseases were reviewed. Results and Conclusions In this review, we discuss the prevalence of COVID‐19 in subjects with asthma, attacks of hereditary angioedema, and other allergic diseases during COVID‐19. Underlying mechanisms suggest a protective role of allergy in COVID‐19, involving eosinophilia, SARS‐CoV‐2 receptors expression, interferon responses, and other immunological events, but further studies are needed to fully understand those associations. There has been significant progress in disease evaluation and management of COVID‐19, and allergy care should continue during the COVID‐19 pandemic. The European Academy of Allergy & Clinical Immunology (EAACI) launched a series of statements and position papers providing recommendations on the organization of the allergy clinic, handling of allergen immunotherapy, asthma, drug hypersensitivity, allergic rhinitis, and other allergic diseases. Treatment of allergies using biologics during the COVID‐19 pandemic has also been discussed. Allergic reactions to the COVID‐19 vaccines, including severe anaphylaxis, have been reported. Vaccination is a prophylactic strategy that can lead to a significant reduction in the mortality and morbidity associated with SARS‐CoV‐2 infection, and in this review, we discuss the proposed culprit components causing rare adverse reactions and recommendations to mitigate the risk of anaphylactic events during the administration of the vaccines.
Since the first reports of coronavirus disease 2019 (COVID-19) in Wuhan, China, in December 2019, there have been 198 million confirmed cases worldwide as of August 2021. The scientific community has joined efforts to gain knowledge of the newly emerged virus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the immunopathological mechanisms leading to COVID-19, and its significance for patients with allergies and asthma.BACKGROUNDSince the first reports of coronavirus disease 2019 (COVID-19) in Wuhan, China, in December 2019, there have been 198 million confirmed cases worldwide as of August 2021. The scientific community has joined efforts to gain knowledge of the newly emerged virus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the immunopathological mechanisms leading to COVID-19, and its significance for patients with allergies and asthma.Based on the current literature, recent advances and developments in COVID-19 in the context of allergic diseases were reviewed.METHODSBased on the current literature, recent advances and developments in COVID-19 in the context of allergic diseases were reviewed.In this review, we discuss the prevalence of COVID-19 in subjects with asthma, attacks of hereditary angioedema, and other allergic diseases during COVID-19. Underlying mechanisms suggest a protective role of allergy in COVID-19, involving eosinophilia, SARS-CoV-2 receptors expression, interferon responses, and other immunological events, but further studies are needed to fully understand those associations. There has been significant progress in disease evaluation and management of COVID-19, and allergy care should continue during the COVID-19 pandemic. The European Academy of Allergy & Clinical Immunology (EAACI) launched a series of statements and position papers providing recommendations on the organization of the allergy clinic, handling of allergen immunotherapy, asthma, drug hypersensitivity, allergic rhinitis, and other allergic diseases. Treatment of allergies using biologics during the COVID-19 pandemic has also been discussed. Allergic reactions to the COVID-19 vaccines, including severe anaphylaxis, have been reported. Vaccination is a prophylactic strategy that can lead to a significant reduction in the mortality and morbidity associated with SARS-CoV-2 infection, and in this review, we discuss the proposed culprit components causing rare adverse reactions and recommendations to mitigate the risk of anaphylactic events during the administration of the vaccines.RESULTS AND CONCLUSIONSIn this review, we discuss the prevalence of COVID-19 in subjects with asthma, attacks of hereditary angioedema, and other allergic diseases during COVID-19. Underlying mechanisms suggest a protective role of allergy in COVID-19, involving eosinophilia, SARS-CoV-2 receptors expression, interferon responses, and other immunological events, but further studies are needed to fully understand those associations. There has been significant progress in disease evaluation and management of COVID-19, and allergy care should continue during the COVID-19 pandemic. The European Academy of Allergy & Clinical Immunology (EAACI) launched a series of statements and position papers providing recommendations on the organization of the allergy clinic, handling of allergen immunotherapy, asthma, drug hypersensitivity, allergic rhinitis, and other allergic diseases. Treatment of allergies using biologics during the COVID-19 pandemic has also been discussed. Allergic reactions to the COVID-19 vaccines, including severe anaphylaxis, have been reported. Vaccination is a prophylactic strategy that can lead to a significant reduction in the mortality and morbidity associated with SARS-CoV-2 infection, and in this review, we discuss the proposed culprit components causing rare adverse reactions and recommendations to mitigate the risk of anaphylactic events during the administration of the vaccines.
Since the first reports of coronavirus disease 2019 (COVID-19) in Wuhan, China, in December 2019, there have been 198 million confirmed cases worldwide as of August 2021. The scientific community has joined efforts to gain knowledge of the newly emerged virus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the immunopathological mechanisms leading to COVID-19, and its significance for patients with allergies and asthma. Based on the current literature, recent advances and developments in COVID-19 in the context of allergic diseases were reviewed. In this review, we discuss the prevalence of COVID-19 in subjects with asthma, attacks of hereditary angioedema, and other allergic diseases during COVID-19. Underlying mechanisms suggest a protective role of allergy in COVID-19, involving eosinophilia, SARS-CoV-2 receptors expression, interferon responses, and other immunological events, but further studies are needed to fully understand those associations. There has been significant progress in disease evaluation and management of COVID-19, and allergy care should continue during the COVID-19 pandemic. The European Academy of Allergy & Clinical Immunology (EAACI) launched a series of statements and position papers providing recommendations on the organization of the allergy clinic, handling of allergen immunotherapy, asthma, drug hypersensitivity, allergic rhinitis, and other allergic diseases. Treatment of allergies using biologics during the COVID-19 pandemic has also been discussed. Allergic reactions to the COVID-19 vaccines, including severe anaphylaxis, have been reported. Vaccination is a prophylactic strategy that can lead to a significant reduction in the mortality and morbidity associated with SARS-CoV-2 infection, and in this review, we discuss the proposed culprit components causing rare adverse reactions and recommendations to mitigate the risk of anaphylactic events during the administration of the vaccines.
Abstract Background Since the first reports of coronavirus disease 2019 (COVID‐19) in Wuhan, China, in December 2019, there have been 198 million confirmed cases worldwide as of August 2021. The scientific community has joined efforts to gain knowledge of the newly emerged virus named severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the immunopathological mechanisms leading to COVID‐19, and its significance for patients with allergies and asthma. Methods Based on the current literature, recent advances and developments in COVID‐19 in the context of allergic diseases were reviewed. Results and Conclusions In this review, we discuss the prevalence of COVID‐19 in subjects with asthma, attacks of hereditary angioedema, and other allergic diseases during COVID‐19. Underlying mechanisms suggest a protective role of allergy in COVID‐19, involving eosinophilia, SARS‐CoV‐2 receptors expression, interferon responses, and other immunological events, but further studies are needed to fully understand those associations. There has been significant progress in disease evaluation and management of COVID‐19, and allergy care should continue during the COVID‐19 pandemic. The European Academy of Allergy & Clinical Immunology (EAACI) launched a series of statements and position papers providing recommendations on the organization of the allergy clinic, handling of allergen immunotherapy, asthma, drug hypersensitivity, allergic rhinitis, and other allergic diseases. Treatment of allergies using biologics during the COVID‐19 pandemic has also been discussed. Allergic reactions to the COVID‐19 vaccines, including severe anaphylaxis, have been reported. Vaccination is a prophylactic strategy that can lead to a significant reduction in the mortality and morbidity associated with SARS‐CoV‐2 infection, and in this review, we discuss the proposed culprit components causing rare adverse reactions and recommendations to mitigate the risk of anaphylactic events during the administration of the vaccines.
BackgroundSince the first reports of coronavirus disease 2019 (COVID‐19) in Wuhan, China, in December 2019, there have been 198 million confirmed cases worldwide as of August 2021. The scientific community has joined efforts to gain knowledge of the newly emerged virus named severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the immunopathological mechanisms leading to COVID‐19, and its significance for patients with allergies and asthma.MethodsBased on the current literature, recent advances and developments in COVID‐19 in the context of allergic diseases were reviewed.Results and ConclusionsIn this review, we discuss the prevalence of COVID‐19 in subjects with asthma, attacks of hereditary angioedema, and other allergic diseases during COVID‐19. Underlying mechanisms suggest a protective role of allergy in COVID‐19, involving eosinophilia, SARS‐CoV‐2 receptors expression, interferon responses, and other immunological events, but further studies are needed to fully understand those associations. There has been significant progress in disease evaluation and management of COVID‐19, and allergy care should continue during the COVID‐19 pandemic. The European Academy of Allergy & Clinical Immunology (EAACI) launched a series of statements and position papers providing recommendations on the organization of the allergy clinic, handling of allergen immunotherapy, asthma, drug hypersensitivity, allergic rhinitis, and other allergic diseases. Treatment of allergies using biologics during the COVID‐19 pandemic has also been discussed. Allergic reactions to the COVID‐19 vaccines, including severe anaphylaxis, have been reported. Vaccination is a prophylactic strategy that can lead to a significant reduction in the mortality and morbidity associated with SARS‐CoV‐2 infection, and in this review, we discuss the proposed culprit components causing rare adverse reactions and recommendations to mitigate the risk of anaphylactic events during the administration of the vaccines.
Author Akdis, Cezmi A.
Akdis, Mübeccel
Veen, Willem
Ding, Mei
Sokolowska, Milena
Sun, Yuan‐li
Azkur, Ahmet Kursat
Gao, Ya‐dong
Azkur, Dilek
Dong, Xiang
AuthorAffiliation 2 Hubei Province Key Laboratory of Allergy and Immunology Wuhan University Wuhan China
5 Department of Virology Faculty of Veterinary Medicine University of Kirikkale Kirikkale Turkey
3 Swiss Institute of Allergy and Asthma Research (SIAF) University of Zurich Davos Switzerland
4 Christine Kühne ‐ Center for Allergy Research and Education (CK‐CARE) Davos Switzerland
6 Division of Pediatric Allergy and Immunology Department of Pediatrics Faculty of Medicine University of Kirikkale Kirikkale Turkey
1 Department of Allergology Zhongnan Hospital of Wuhan University Wuhan China
AuthorAffiliation_xml – name: 1 Department of Allergology Zhongnan Hospital of Wuhan University Wuhan China
– name: 4 Christine Kühne ‐ Center for Allergy Research and Education (CK‐CARE) Davos Switzerland
– name: 2 Hubei Province Key Laboratory of Allergy and Immunology Wuhan University Wuhan China
– name: 6 Division of Pediatric Allergy and Immunology Department of Pediatrics Faculty of Medicine University of Kirikkale Kirikkale Turkey
– name: 3 Swiss Institute of Allergy and Asthma Research (SIAF) University of Zurich Davos Switzerland
– name: 5 Department of Virology Faculty of Veterinary Medicine University of Kirikkale Kirikkale Turkey
Author_xml – sequence: 1
  givenname: Mei
  orcidid: 0000-0001-7647-5166
  surname: Ding
  fullname: Ding, Mei
  organization: Wuhan University
– sequence: 2
  givenname: Xiang
  orcidid: 0000-0002-5241-4307
  surname: Dong
  fullname: Dong, Xiang
  organization: Wuhan University
– sequence: 3
  givenname: Yuan‐li
  surname: Sun
  fullname: Sun, Yuan‐li
  organization: Wuhan University
– sequence: 4
  givenname: Milena
  orcidid: 0000-0001-9710-6685
  surname: Sokolowska
  fullname: Sokolowska, Milena
  organization: Christine Kühne ‐ Center for Allergy Research and Education (CK‐CARE)
– sequence: 5
  givenname: Mübeccel
  orcidid: 0000-0003-0554-9943
  surname: Akdis
  fullname: Akdis, Mübeccel
  organization: University of Zurich
– sequence: 6
  givenname: Willem
  orcidid: 0000-0001-9951-6688
  surname: Veen
  fullname: Veen, Willem
  organization: University of Zurich
– sequence: 7
  givenname: Ahmet Kursat
  orcidid: 0000-0002-5597-8917
  surname: Azkur
  fullname: Azkur, Ahmet Kursat
  organization: University of Kirikkale
– sequence: 8
  givenname: Dilek
  orcidid: 0000-0002-4396-9087
  surname: Azkur
  fullname: Azkur, Dilek
  organization: University of Kirikkale
– sequence: 9
  givenname: Cezmi A.
  orcidid: 0000-0001-8020-019X
  surname: Akdis
  fullname: Akdis, Cezmi A.
  email: akdisac@siaf.uzh.ch
  organization: Christine Kühne ‐ Center for Allergy Research and Education (CK‐CARE)
– sequence: 10
  givenname: Ya‐dong
  orcidid: 0000-0003-1251-7608
  surname: Gao
  fullname: Gao, Ya‐dong
  email: gaoyadong@whu.edu.cn, akdisac@siaf.uzh.ch
  organization: Wuhan University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34582102$$D View this record in MEDLINE/PubMed
BookMark eNp9ks9uEzEQxleoiJbSCw-AVuKCkFJsr-3dvSChlD-RIlWqCldr1h6njhw7rDeB3voIPCNPgjcpVVsh5mJ75vd9GtvzvDgIMWBRvKTklBLC3mk_sFPKiBRPiiNGuJjUhLGDe_vD4iSlJckhmiwhz4rDiouGUcKOiosL1BiGEswWgsZUQjClwS36uF7lQipdKKfn32Znv29-0XY8DVdY6hgG_DmU0ZbgPfYLp0vjEkLC9KJ4asEnPLldj4uvnz5eTr9M5uefZ9MP84kWnImJaVAKDQwlSGS2blrUHDirDPCcEXVbtaRmVCPRvNJ1RxsrkaM0hOsKWXVczPa-JsJSrXu3gv5aRXBql4j9QkE_OO1RNdhVYDUiEMs7qKBrrDWsshWtrWh59nq_91pvuhWa8Ul68A9MH1aCu1KLuFWN5FKSNhu8uTXo4_cNpkGtXNLoPQSMm6SYqGsuRY6Mvn6ELuOmD_mpFKvpjiNjR6_ud3TXyt-vy8DbPaD7mFKP9g6hRI2jocbRULvRyDB5BGs3wODieBvn_y2he8kP5_H6P-ZqOr9ke80fYTfK-g
CitedBy_id crossref_primary_10_1002_alr_23090
crossref_primary_10_1016_j_ijid_2022_09_019
crossref_primary_10_3389_fimmu_2023_1284047
crossref_primary_10_1002_ctm2_717
crossref_primary_10_1111_all_15454
crossref_primary_10_1016_j_waojou_2023_100741
Cites_doi 10.1016/j.jaip.2020.12.045
10.1111/all.14455
10.1111/all.14537
10.1111/all.14793
10.1001/jama.2020.8711
10.1111/all.14767
10.1186/s13601‐020‐00362‐7
10.1111/all.14725
10.1016/j.jmii.2020.03.005
10.1111/all.14449
10.1111/all.14589
10.15585/mmwr.mm6915e3
10.1128/mBio.00907‐20
10.1111/all.14522
10.1111/all.14609
10.1016/j.jaci.2018.08.022
10.1038/nri3831
10.1001/jama.2020.15276
10.1111/all.14675
10.1189/jlb.3RU0315‐099R
10.1016/j.jaci.2020.05.004
10.1056/NEJMoa2034577
10.1111/all.14972
10.1111/all.14569
10.1111/all.14739
10.1056/NEJMoa2107058
10.1056/NEJMoa2027906
10.1056/NEJMoa2101544
10.1136/bcr.02.2012.5797
10.1111/all.14629
10.1016/s0140‐6736(20)32623‐4
10.1111/all.14796
10.1186/s13601‐020‐00323‐0
10.1111/all.14697
10.1016/j.anai.2020.07.029
10.1056/NEJMoa2107456
10.1111/all.14726
10.1111/all.14711
10.1016/j.jaci.2020.07.026
10.1016/j.jaci.2017.11.051
10.1111/all.14787
10.1111/all.14420
10.1111/all.14302
10.1111/all.14462
10.1056/NEJMoa2108891
10.1007/s11882‐015‐0525‐1
10.1111/all.14654
10.1126/science.abc2061
10.1016/s0140‐6736(21)00448‐7
10.1111/all.14966
10.1111/all.14353
10.4049/jimmunol.148.7.2142
10.1111/all.14728
10.1111/all.14894
10.1111/all.14596
10.1093/infdis/jiab288
10.1111/all.14439
10.1016/s0140‐6736(20)32579‐4
10.1001/jama.2021.0600
10.1111/all.14761
10.1111/all.14818
10.1111/all.14238
10.1111/all.14361
10.1111/cea.12882
10.1111/all.14473
10.1111/all.14456
10.1111/all.14687
10.4049/jimmunol.1600787
10.1111/all.14601
10.1016/j.jaci.2020.04.021
10.1126/science.abc6027
10.1038/s41577‐021‐00516‐z
10.1038/s41467‐020‐18781‐2
10.1056/NEJMc2101951
10.1056/NEJMoa2104983
10.1111/all.14831
10.1111/all.14289
10.1101/2020.05.06.20092957
10.1073/pnas.2019034118
10.1111/all.14482
10.1111/all.14516
10.1111/all.14426
10.1016/j.jaci.2008.08.028
10.1016/j.jaci.2020.06.010
10.1111/all.14336
10.1056/NEJMoa2107659
10.1111/all.14551
10.1111/all.14593
10.1016/j.chom.2016.01.007
10.1111/all.14794
10.1111/all.14904
10.1111/all.14591
10.1111/all.14567
10.1002/clt2.12044
10.1111/all.14453
10.1111/all.14873
10.1016/j.jinf.2004.05.018
10.1111/all.14774
10.1056/NEJMp2005835
10.1016/j.eclinm.2020.100375
10.1016/j.jaci.2020.04.009
10.1111/all.14407
10.1111/all.14876
10.1111/all.14348
10.1111/all.14534
10.1111/all.14558
10.1111/all.14838
10.1016/j.jaci.2020.09.017
10.1016/j.jaci.2004.11.053
10.1001/jama.2020.21231
10.4049/jimmunol.1102299
10.1016/s0140‐6736(20)30818‐7
10.1111/all.14498
10.1111/all.14467
10.1111/all.14653
10.1164/rccm.202003‐0543OC
10.1111/all.14429
10.1111/all.13786
10.1016/s0140‐6736(20)32317‐5
10.1111/all.14840
10.1111/all.14722
10.1111/all.12627
10.1111/all.14549
10.1111/all.14734
10.1056/NEJMp2003539
10.1111/all.14472
10.1038/s41586‐021‐03234‐7
10.1016/j.jaip.2020.03.012
10.1111/all.14708
10.1111/all.14434
10.1001/jama.2020.8391
10.1126/science.abb4218
10.1016/j.jaci.2020.08.008
10.1016/s1473‐3099(20)30270‐x
10.1111/all.14532
10.1093/infdis/jiaa189
10.1111/all.14471
ContentType Journal Article
Copyright 2021 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2021 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
– notice: 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
COVID
DWQXO
FYUFA
GHDGH
K9.
M0S
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1002/clt2.12065
DatabaseName Wiley-Blackwell Open Access Titles
CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
Coronavirus Research Database
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
Coronavirus Research Database
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
ProQuest Health & Medical Research Collection
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
PubMed

Publicly Available Content Database
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: PIMPY
  name: ProQuest Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-7022
EndPage n/a
ExternalDocumentID oai_doaj_org_article_8eb3afceea0f4ba3ab8ffd23f317f594
PMC8646609
34582102
10_1002_clt2_12065
CLT212065
Genre letter
Letter
Correspondence
GeographicLocations United Kingdom--UK
GeographicLocations_xml – name: United Kingdom--UK
GroupedDBID 0R~
1OC
24P
2VQ
53G
5VS
7X7
8FI
8FJ
AAFWJ
AAMMB
ABDBF
ABUWG
ACCMX
ACGFS
ACUHS
ADBBV
ADPDF
ADRAZ
ADUKV
AEFGJ
AFKRA
AFPKN
AGXDD
AHBYD
AHSBF
AHYZX
AIDQK
AIDYY
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMKLP
AOIJS
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
DIK
EBS
FYUFA
GROUPED_DOAJ
GX1
H13
HMCUK
HYE
IAO
IHR
IHW
IPNFZ
ITC
KQ8
M48
M~E
OK1
OVD
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RBZ
RIG
ROL
RPM
RSV
SMD
SOJ
TEORI
UKHRP
AAYXX
AFFHD
CITATION
WIN
AAHHS
ACCFJ
AEEZP
AEQDE
AIWBW
AJBDE
NPM
3V.
7XB
8FK
AZQEC
COVID
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c5425-d8e65ca2e6a6e2f789ec4a423da4a6e579390721ce0c43c7b18f6e4e6d04c3e23
IEDL.DBID DOA
ISICitedReferencesCount 6
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000700512800005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2045-7022
IngestDate Mon Nov 10 04:30:27 EST 2025
Tue Nov 04 01:59:46 EST 2025
Fri Sep 05 12:00:16 EDT 2025
Tue Oct 07 06:49:25 EDT 2025
Thu Apr 03 06:56:39 EDT 2025
Sat Nov 29 06:29:18 EST 2025
Tue Nov 18 22:42:34 EST 2025
Sun Jul 06 04:45:02 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords COVID-19
Mechanismen
treatment
Therapie
Impfung
Schlüsselwörter: Allergie
allergy
mechanism
vaccination
Language English
License Attribution
http://creativecommons.org/licenses/by/4.0
2021 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5425-d8e65ca2e6a6e2f789ec4a423da4a6e579390721ce0c43c7b18f6e4e6d04c3e23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Correspondence-1
ORCID 0000-0001-9710-6685
0000-0001-9951-6688
0000-0002-4396-9087
0000-0002-5597-8917
0000-0003-0554-9943
0000-0002-5241-4307
0000-0003-1251-7608
0000-0001-8020-019X
0000-0001-7647-5166
OpenAccessLink https://doaj.org/article/8eb3afceea0f4ba3ab8ffd23f317f594
PMID 34582102
PQID 2715774604
PQPubID 2040244
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_8eb3afceea0f4ba3ab8ffd23f317f594
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8646609
proquest_miscellaneous_2577465555
proquest_journals_2715774604
pubmed_primary_34582102
crossref_primary_10_1002_clt2_12065
crossref_citationtrail_10_1002_clt2_12065
wiley_primary_10_1002_clt2_12065_CLT212065
PublicationCentury 2000
PublicationDate september 2021
PublicationDateYYYYMMDD 2021-09-01
PublicationDate_xml – month: 09
  year: 2021
  text: september 2021
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Hoboken
PublicationTitle Clinical and translational allergy
PublicationTitleAlternate Clin Transl Allergy
PublicationYear 2021
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Wiley
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
– name: Wiley
References 2021; 9
2018; 142
2015; 15
2021; 21
2016; 19
2020; 20
2020; 383
2012
2015; 70
2020; 382
2019; 74
2017; 47
2004; 49
2021; 224
2005; 115
2021; 325
2015; 98
1992; 148
2020; 369
2020; 368
2020; 324
2021; 384
2020; 146
2020; 11
2020; 323
2020; 125
2020; 10
2020; 201
2017; 198
2021; 385
2008; 122
2019; 143
2020; 8
2021; 76
2021; 11
2020; 75
2020; 53
2021
2020; 396
2020
2020; 395
1984; 33
2021; 118
2021; 591
2020; 69
2020; 23
2021; 397
2011; 187
e_1_2_8_26_1
e_1_2_8_49_1
e_1_2_8_68_1
e_1_2_8_132_1
e_1_2_8_5_1
e_1_2_8_9_1
e_1_2_8_117_1
e_1_2_8_22_1
e_1_2_8_45_1
e_1_2_8_64_1
e_1_2_8_87_1
e_1_2_8_113_1
e_1_2_8_136_1
e_1_2_8_41_1
e_1_2_8_60_1
e_1_2_8_83_1
e_1_2_8_19_1
e_1_2_8_109_1
e_1_2_8_15_1
e_1_2_8_38_1
e_1_2_8_57_1
e_1_2_8_120_1
e_1_2_8_91_1
e_1_2_8_95_1
e_1_2_8_99_1
e_1_2_8_105_1
e_1_2_8_128_1
e_1_2_8_11_1
e_1_2_8_34_1
e_1_2_8_53_1
e_1_2_8_76_1
e_1_2_8_101_1
e_1_2_8_124_1
e_1_2_8_30_1
e_1_2_8_72_1
e_1_2_8_29_1
e_1_2_8_25_1
e_1_2_8_48_1
e_1_2_8_2_1
e_1_2_8_133_1
e_1_2_8_110_1
e_1_2_8_6_1
e_1_2_8_21_1
e_1_2_8_67_1
e_1_2_8_44_1
e_1_2_8_86_1
e_1_2_8_118_1
e_1_2_8_63_1
e_1_2_8_137_1
e_1_2_8_40_1
e_1_2_8_82_1
e_1_2_8_114_1
e_1_2_8_18_1
e_1_2_8_14_1
e_1_2_8_37_1
e_1_2_8_79_1
e_1_2_8_94_1
e_1_2_8_90_1
e_1_2_8_121_1
e_1_2_8_98_1
e_1_2_8_10_1
e_1_2_8_56_1
e_1_2_8_106_1
e_1_2_8_33_1
e_1_2_8_75_1
e_1_2_8_129_1
e_1_2_8_52_1
e_1_2_8_102_1
e_1_2_8_71_1
e_1_2_8_125_1
e_1_2_8_28_1
e_1_2_8_24_1
e_1_2_8_47_1
e_1_2_8_3_1
e_1_2_8_81_1
e_1_2_8_111_1
e_1_2_8_130_1
e_1_2_8_7_1
e_1_2_8_20_1
e_1_2_8_43_1
e_1_2_8_66_1
e_1_2_8_89_1
e_1_2_8_119_1
e_1_2_8_138_1
e_1_2_8_62_1
e_1_2_8_85_1
e_1_2_8_115_1
e_1_2_8_134_1
e_1_2_8_17_1
e_1_2_8_13_1
e_1_2_8_36_1
e_1_2_8_59_1
e_1_2_8_70_1
e_1_2_8_122_1
e_1_2_8_97_1
e_1_2_8_32_1
e_1_2_8_55_1
e_1_2_8_78_1
e_1_2_8_107_1
e_1_2_8_51_1
e_1_2_8_74_1
e_1_2_8_103_1
e_1_2_8_126_1
e_1_2_8_93_1
e_1_2_8_46_1
e_1_2_8_27_1
e_1_2_8_69_1
e_1_2_8_80_1
e_1_2_8_4_1
e_1_2_8_131_1
e_1_2_8_8_1
e_1_2_8_42_1
e_1_2_8_88_1
e_1_2_8_116_1
e_1_2_8_23_1
e_1_2_8_65_1
e_1_2_8_139_1
e_1_2_8_84_1
e_1_2_8_112_1
e_1_2_8_61_1
e_1_2_8_39_1
e_1_2_8_35_1
e_1_2_8_16_1
e_1_2_8_58_1
e_1_2_8_92_1
(e_1_2_8_135_1) 1984; 33
e_1_2_8_96_1
e_1_2_8_100_1
e_1_2_8_31_1
e_1_2_8_77_1
e_1_2_8_127_1
e_1_2_8_12_1
e_1_2_8_54_1
e_1_2_8_108_1
e_1_2_8_73_1
e_1_2_8_123_1
e_1_2_8_50_1
e_1_2_8_104_1
References_xml – volume: 20
  start-page: 1013
  year: 2020
  end-page: 1014
  article-title: Baricitinib for COVID‐19: a suitable treatment?–Authors' reply
  publication-title: Lancet Infect Dis
– volume: 146
  start-page: 790
  year: 2020
  end-page: 798
  article-title: Allergic disorders and susceptibility to and severity of COVID‐19: a nationwide cohort study
  publication-title: J Allergy Clin Immunol
– volume: 591
  start-page: 124
  year: 2021
  end-page: 130
  article-title: Global absence and targeting of protective immune states in severe COVID‐19
  publication-title: Nature
– volume: 9
  start-page: 1152
  year: 2021
  end-page: 1162
  article-title: Eosinophilia in asthma patients is protective against severe COVID‐19 illness
  publication-title: J Allergy Clin Immunol Pract
– volume: 76
  start-page: 1911
  year: 2021
  end-page: 1913
  article-title: Genetic predisposition to allergic diseases is inversely associated with risk of COVID‐19
  publication-title: Allergy
– volume: 76
  start-page: 586
  year: 2021
  end-page: 588
  article-title: Asthma control, self‐management, and healthcare access during the COVID‐19 epidemic in Beijing
  publication-title: Allergy
– volume: 76
  start-page: 949
  year: 2021
  end-page: 950
  article-title: Treating venom allergy during COVID‐19 pandemic
  publication-title: Allergy
– volume: 382
  start-page: 1679
  year: 2020
  end-page: 1681
  article-title: Virtually perfect? Telemedicine for Covid‐19
  publication-title: N Engl J Med
– volume: 75
  start-page: 1819
  year: 2020
  end-page: 1822
  article-title: COVID‐19, chronic inflammatory respiratory diseases and eosinophils‐Observations from reported clinical case series
  publication-title: Allergy
– volume: 76
  start-page: 959
  year: 2021
  end-page: 960
  article-title: Are severe asthma patients at higher risk of developing severe outcomes from COVID‐19?
  publication-title: Allergy
– volume: 385
  start-page: 585
  year: 2021
  end-page: 594
  article-title: Effectiveness of COVID‐19 vaccines against the B.1.617.2 (delta) variant
  publication-title: N Engl J Med
– volume: 146
  start-page: 1295
  year: 2020
  end-page: 1301
  article-title: Asthma‐associated risk for COVID‐19 development
  publication-title: J Allergy Clin Immunol
– volume: 323
  start-page: 2512
  year: 2020
  end-page: 2514
  article-title: Olfactory dysfunction in COVID‐19: diagnosis and management
  publication-title: J Am Med Assoc
– volume: 148
  start-page: 2142
  year: 1992
  end-page: 2147
  article-title: Reciprocal regulatory effects of IFN‐gamma and IL‐4 on the in vitro development of human Th1 and Th2 clones
  publication-title: J Immunol
– volume: 76
  start-page: 1941
  year: 2021
  end-page: 1942
  article-title: Other excipients than PEG might cause serious hypersensitivity reactions in COVID‐19 vaccines
  publication-title: Allergy
– volume: 146
  start-page: 1
  year: 2020
  end-page: 7
  article-title: Eosinophil responses during COVID‐19 infections and coronavirus vaccination
  publication-title: J Allergy Clin Immunol
– volume: 76
  start-page: 957
  year: 2021
  end-page: 958
  article-title: Dupilumab, severe asthma airway responses, and SARS‐CoV‐2 serology
  publication-title: Allergy
– volume: 324
  start-page: 2555
  year: 2020
  end-page: 2557
  article-title: Psychological distress and COVID‐19‐related stressors reported in a longitudinal cohort of US adults in April and July 2020
  publication-title: Jama
– year: 2012
  article-title: Hypersensitivity reaction to human papillomavirus vaccine due to polysorbate 80
  publication-title: BMJ Case Rep
– volume: 76
  start-page: 921
  year: 2021
  end-page: 924
  article-title: Association between asthma and clinical mortality/morbidity in COVID‐19 patients using clinical epidemiologic data from Korean Disease Control and Prevention
  publication-title: Allergy
– volume: 198
  start-page: 3214
  year: 2017
  end-page: 3226
  article-title: Eosinophils promote antiviral immunity in mice infected with influenza A virus
  publication-title: J Immunol
– volume: 76
  start-page: 906
  year: 2021
  end-page: 910
  article-title: Angiotensin‐converting enzyme II expression and its implication in the association between COVID‐19 and allergic rhinitis
  publication-title: Allergy
– volume: 69
  start-page: 458
  year: 2020
  end-page: 464
  article-title: Hospitalization rates and characteristics of patients hospitalized with laboratory‐confirmed coronavirus disease 2019 ‐ COVID‐NET, 14 states, March 1–30, 2020
  publication-title: MMWR Morb Mortal Wkly Rep
– volume: 76
  start-page: 677
  year: 2021
  end-page: 688
  article-title: Management of patients with chronic rhinosinusitis during the COVID‐19 pandemic‐An EAACI position paper
  publication-title: Allergy
– volume: 115
  start-page: 459
  year: 2005
  end-page: 465
  article-title: The anti‐inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation
  publication-title: J Allergy Clin Immunol
– volume: 384
  start-page: 2187
  year: 2021
  end-page: 2201
  article-title: Safety and efficacy of single‐dose Ad26.COV2.S vaccine against covid‐19
  publication-title: N Engl J Med
– volume: 76
  start-page: 963
  year: 2021
  end-page: 965
  article-title: Asthmatic patients and COVID‐19: different disease course?
  publication-title: Allergy
– volume: 76
  start-page: 2535
  year: 2021
  end-page: 2543
  article-title: Impact of anxiety, stress and depression related to COVID‐19 pandemic on the course of hereditary angioedema with C1‐inhibitor deficiency
  publication-title: Allergy
– volume: 397
  year: 2021
  article-title: Climate and COVID‐19: converging crises
  publication-title: Lancet
– volume: 19
  start-page: 181
  year: 2016
  end-page: 193
  article-title: Dysregulated type I interferon and inflammatory monocyte‐macrophage responses cause lethal pneumonia in SARS‐CoV‐infected mice
  publication-title: Cell Host Microbe
– volume: 75
  start-page: 2764
  year: 2020
  end-page: 2774
  article-title: Considerations on biologicals for patients with allergic disease in times of the COVID‐19 pandemic: an EAACI statement
  publication-title: Allergy
– volume: 15
  year: 2015
  article-title: Cutaneous and systemic mastocytosis in children: a risk factor for anaphylaxis?
  publication-title: Curr Allergy Asthma Rep
– volume: 76
  start-page: 868
  year: 2021
  end-page: 870
  article-title: Telemedicine allows quantitative measuring of olfactory dysfunction in COVID‐19
  publication-title: Allergy
– volume: 384
  start-page: 1775
  year: 2021
  end-page: 1777
  article-title: BNT162b2 mRNA covid‐19 vaccine effectiveness among health care workers
  publication-title: N Engl J Med
– volume: 23
  year: 2020
  article-title: Eosinopenia and elevated C‐reactive protein facilitate triage of COVID‐19 patients in fever clinic: a retrospective case‐control study
  publication-title: EClinicalMedicine
– volume: 8
  start-page: 1477
  year: 2020
  end-page: 1488
  article-title: COVID‐19: pandemic contingency planning for the allergy and immunology clinic
  publication-title: J Allergy Clin Immunol Pract
– volume: 74
  start-page: 1611
  year: 2019
  end-page: 1630
  article-title: Management of ocular allergy
  publication-title: Allergy
– year: 2021
  article-title: Safety and efficacy of NVX‐CoV2373 covid‐19 vaccine
  publication-title: N Engl J Med
– volume: 75
  start-page: 2503
  year: 2020
  end-page: 2541
  article-title: A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2
  publication-title: Allergy
– volume: 323
  start-page: 2458
  year: 2020
  end-page: 2459
  article-title: Planning for a COVID‐19 vaccination program
  publication-title: Jama
– volume: 76
  start-page: 2998
  year: 2021
  end-page: 2901
  article-title: Asia‐Pacific perspectives on the COVID‐19 pandemic
  publication-title: Allergy
– volume: 76
  start-page: 1938
  year: 2021
  end-page: 1940
  article-title: COVID‐19 vaccine anaphylaxis: IgE, complement or what else? A reply to: COVID‐19 vaccine anaphylaxis: PEG or not?
  publication-title: Allergy
– volume: 75
  start-page: 1543
  year: 2020
  end-page: 1545
  article-title: Asthma and COVID‐19: is asthma a risk factor for severe outcomes?
  publication-title: Allergy
– volume: 75
  start-page: 1730
  year: 2020
  end-page: 1741
  article-title: Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China
  publication-title: Allergy
– volume: 324
  start-page: 1133
  year: 2020
  end-page: 1134
  article-title: Dermatology and COVID‐19
  publication-title: Jama
– volume: 76
  start-page: 866
  year: 2021
  end-page: 868
  article-title: Is asthma protective against COVID‐19?
  publication-title: Allergy
– volume: 76
  start-page: 1934
  year: 2021
  end-page: 1937
  article-title: COVID‐19 vaccine anaphylaxis: PEG or not?
  publication-title: Allergy
– volume: 76
  start-page: 915
  year: 2021
  end-page: 917
  article-title: Small droplet emission in exhaled breath during different breathing manoeuvres: implications for clinical lung function testing during COVID‐19
  publication-title: Allergy
– volume: 49
  start-page: 179
  year: 2004
  end-page: 209
  article-title: A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines
  publication-title: J Infect
– volume: 33
  start-page: 185
  year: 1984
  end-page: 187
  article-title: Systemic allergic reactions following immunization with human diploid cell rabies vaccine
  publication-title: MMWR Morb Mortal Wkly Rep
– volume: 76
  start-page: 1624
  year: 2021
  end-page: 1628
  article-title: ARIA‐EAACI statement on severe allergic reactions to COVID‐19 vaccines ‐ an EAACI‐ARIA Position Paper
  publication-title: Allergy
– volume: 146
  start-page: 307
  year: 2020
  end-page: 314
  article-title: Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID‐19
  publication-title: J Allergy Clin Immunol
– volume: 76
  start-page: 953
  year: 2021
  end-page: 954
  article-title: Update on asthma prevalence in severe COVID‐19 patients
  publication-title: Allergy
– year: 2021
  article-title: Asthma phenotypes, associated comorbidities, and long‐term symptoms in COVID‐19
  publication-title: Allergy
– volume: 75
  start-page: 2445
  year: 2020
  end-page: 2476
  article-title: Immunology of COVID‐19: mechanisms, clinical outcome, diagnostics, and perspectives‐A report of the European Academy of allergy and clinical immunology (EAACI)
  publication-title: Allergy
– volume: 76
  start-page: 816
  year: 2021
  end-page: 830
  article-title: The global impact of the COVID‐19 pandemic on the management and course of chronic urticaria
  publication-title: Allergy
– volume: 15
  start-page: 271
  year: 2015
  end-page: 282
  article-title: Type 2 cytokines: mechanisms and therapeutic strategies
  publication-title: Nat Rev Immunol
– volume: 76
  start-page: 968
  year: 2021
  end-page: 968
  article-title: Reply to “cabbage and COVID‐19”
  publication-title: Allergy
– volume: 122
  start-page: 969
  year: 2008
  end-page: 976
  article-title: Aberrant function of peripheral blood myeloid and plasmacytoid dendritic cells in atopic dermatitis patients
  publication-title: J Allergy Clin Immunol
– volume: 395
  start-page: 1180
  year: 2020
  end-page: 1181
  article-title: Virtual health care in the era of COVID‐19
  publication-title: Lancet
– volume: 385
  start-page: 320
  year: 2021
  end-page: 329
  article-title: Prevention and attenuation of COVID‐19 with the BNT162b2 and mRNA‐1273 vaccines
  publication-title: N Engl J Med
– volume: 53
  start-page: 368
  year: 2020
  end-page: 370
  article-title: TH17 responses in cytokine storm of COVID‐19: an emerging target of JAK2 inhibitor Fedratinib
  publication-title: J Microbiol Immunol Infect
– year: 2021
  article-title: Management of anaphylaxis due to COVID‐19 vaccines in the elderly
  publication-title: Allergy
– volume: 76
  start-page: 887
  year: 2021
  end-page: 892
  article-title: COVID‐19 in Severe Asthma Network in Italy (SANI) patients: clinical features, impact of comorbidities and treatments
  publication-title: Allergy
– volume: 75
  start-page: 2775
  year: 2020
  end-page: 2793
  article-title: Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: an EAACI Position Paper
  publication-title: Allergy
– volume: 383
  start-page: 2439
  year: 2020
  end-page: 2450
  article-title: Safety and immunogenicity of two RNA‐based COVID‐19 vaccine candidates
  publication-title: N Engl J Med
– volume: 98
  start-page: 185
  year: 2015
  end-page: 194
  article-title: Interferon at the crossroads of allergy and viral infections
  publication-title: J Leukoc Biol
– volume: 146
  start-page: 1027
  year: 2020
  end-page: 1034
  article-title: Asthma among hospitalized patients with COVID‐19 and related outcomes
  publication-title: J Allergy Clin Immunol
– volume: 76
  start-page: 2624
  year: 2021
  end-page: 2626
  article-title: Anaphylaxis in the emergency department unit: before and during COVID‐19
  publication-title: Allergy
– volume: 11
  year: 2020
  article-title: Type 2 and interferon inflammation regulate SARS‐CoV‐2 entry factor expression in the airway epithelium
  publication-title: Nat Commun
– volume: 76
  start-page: 899
  year: 2021
  end-page: 902
  article-title: Atopic status protects from severe complications of COVID‐19
  publication-title: Allergy
– volume: 224
  start-page: 777
  year: 2021
  end-page: 782
  article-title: Type I, II, and III interferon signatures correspond to COVID‐19 disease severity
  publication-title: J Infect Dis
– volume: 76
  start-page: 2776
  year: 2021
  end-page: 2784
  article-title: Real‐life impact of COVID‐19 pandemic lockdown on the management of pediatric and adult asthma: a survey by the EAACI Asthma Section
  publication-title: Allergy
– volume: 10
  year: 2020
  article-title: Nrf2‐interacting nutrients and COVID‐19: time for research to develop adaptation strategies
  publication-title: Clin Transl Allergy
– volume: 76
  start-page: 689
  year: 2021
  end-page: 697
  article-title: ARIA‐EAACI statement on asthma and COVID‐19 (June 2, 2020)
  publication-title: Allergy
– volume: 397
  start-page: 875
  year: 2021
  end-page: 877
  article-title: Early rate reductions of SARS‐CoV‐2 infection and COVID‐19 in BNT162b2 vaccine recipients
  publication-title: Lancet
– volume: 125
  start-page: 707
  year: 2020
  end-page: 709
  article-title: Clinical course and outcomes of patients with asthma hospitalized for severe acute respiratory syndrome coronavirus 2 pneumonia: a single‐center, retrospective study
  publication-title: Ann Allergy Asthma Immunol
– volume: 75
  start-page: 2705
  year: 2020
  end-page: 2708
  article-title: COVID‐19 in a patient with severe asthma treated with Omalizumab
  publication-title: Allergy
– volume: 76
  start-page: 1629
  year: 2021
  end-page: 1639
  article-title: EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID‐19 vaccines
  publication-title: Allergy
– volume: 201
  start-page: 1372
  year: 2020
  end-page: 1379
  article-title: Clinical features of 85 fatal cases of COVID‐19 from Wuhan. A retrospective observational study
  publication-title: Am J Respir Crit Care Med
– volume: 76
  start-page: 1813
  year: 2021
  end-page: 1824
  article-title: Management of patients with atopic dermatitis undergoing systemic therapy during COVID‐19 pandemic in Italy: data from the DA‐COVID‐19 registry
  publication-title: Allergy
– volume: 76
  start-page: 955
  year: 2021
  end-page: 956
  article-title: Asthma phenotypes, comorbidities, and disease activity in COVID‐19: the need of risk stratification
  publication-title: Allergy
– volume: 76
  start-page: 1943
  year: 2021
  end-page: 1944
  article-title: COVID‐19 vaccines and the role of other potential allergenic components different from PEG. A reply to: “Other excipients than PEG might cause serious hypersensitivity reactions in COVID‐19 vaccines”
  publication-title: Allergy
– volume: 118
  year: 2021
  article-title: Higher airborne pollen concentrations correlated with increased SARS‐CoV‐2 infection rates, as evidenced from 31 countries across the globe
  publication-title: Proc Natl Acad Sci U. S. A
– volume: 76
  start-page: 2647
  year: 2021
  end-page: 2649
  article-title: Pros and cons for the role of air pollution on COVID‐19 development
  publication-title: Allergy
– volume: 47
  start-page: 593
  year: 2017
  end-page: 596
  article-title: Vaccination management in children and adults with mastocytosis
  publication-title: Clin Exp Allergy
– year: 2020
  article-title: Associations with Covid‐19 hospitalisation amongst 406,793 adults: the UK Biobank prospective cohort study
  publication-title: medRxiv
– volume: 76
  start-page: 698
  year: 2021
  end-page: 713
  article-title: SARS‐CoV‐2, COVID‐19, skin and immunology ‐ what do we know so far?
  publication-title: Allergy
– volume: 76
  start-page: 1617
  year: 2021
  end-page: 1618
  article-title: Allergic reactions to the first COVID‐19 vaccine: a potential role of polyethylene glycol?
  publication-title: Allergy
– volume: 368
  start-page: 493
  year: 2020
  end-page: 497
  article-title: The effect of human mobility and control measures on the COVID‐19 epidemic in China
  publication-title: Science
– volume: 76
  start-page: 925
  year: 2021
  end-page: 927
  article-title: The role of circulating eosinophils on COVID‐19 mortality varies by race/ethnicity
  publication-title: Allergy
– volume: 187
  start-page: 6059
  year: 2011
  end-page: 6068
  article-title: Eosinophils regulate dendritic cells and Th2 pulmonary immune responses following allergen provocation
  publication-title: J Immunol
– volume: 369
  start-page: 718
  year: 2020
  end-page: 724
  article-title: Impaired type I interferon activity and inflammatory responses in severe COVID‐19 patients
  publication-title: Science
– volume: 75
  start-page: 1699
  year: 2020
  end-page: 1709
  article-title: Eleven faces of coronavirus disease 2019
  publication-title: Allergy
– year: 2021
  article-title: Adherence to subcutaneous immunotherapy with aeroallergens in real‐life practice during the COVID‐19 pandemic
  publication-title: Allergy
– volume: 76
  start-page: 622
  year: 2021
  end-page: 625
  article-title: COVID‐19: a series of important recent clinical and laboratory reports in immunology and pathogenesis of SARS‐CoV‐2 infection and care of allergy patients
  publication-title: Allergy
– volume: 21
  start-page: 202
  year: 2021
  end-page: 203
  article-title: SARS‐CoV‐2 infection and COVID‐19 in asthmatics: a complex relationship
  publication-title: Nat Rev Immunol
– year: 2020
  article-title: Airborne or droplet precautions for health workers treating COVID‐19?
  publication-title: J Infect Dis
– volume: 75
  start-page: 2440
  year: 2020
  end-page: 2444
  article-title: Intranasal corticosteroids in allergic rhinitis in COVID‐19 infected patients: an ARIA‐EAACI statement
  publication-title: Allergy
– volume: 76
  start-page: 875
  year: 2021
  end-page: 878
  article-title: SARS‐CoV‐2 receptor ACE2 protein expression in serum is significantly associated with age
  publication-title: Allergy
– volume: 75
  start-page: 2829
  year: 2020
  end-page: 2845
  article-title: Distribution of ACE2, CD147, CD26, and other SARS‐CoV‐2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID‐19 risk factors
  publication-title: Allergy
– volume: 76
  start-page: 2407
  year: 2021
  end-page: 2419
  article-title: Multidisciplinary consensus on sputum induction biosafety during the COVID‐19 pandemic
  publication-title: Allergy
– volume: 325
  start-page: 780
  year: 2021
  end-page: 781
  article-title: Allergic reactions including anaphylaxis After receipt of the first dose of pfizer‐BioNTech COVID‐19 vaccine
  publication-title: Jama
– volume: 76
  start-page: 1640
  year: 2021
  end-page: 1660
  article-title: Vaccines and allergic reactions: the past, the current COVID‐19 pandemic, and future perspectives
  publication-title: Allergy
– volume: 396
  start-page: 1630
  year: 2020
  article-title: Widespread smell testing for COVID‐19 has limited application
  publication-title: Lancet
– volume: 76
  start-page: 1621
  year: 2021
  end-page: 1623
  article-title: Allergic reactions to COVID‐19 vaccinations‐unveiling the secret(s)
  publication-title: Allergy
– volume: 76
  start-page: 918
  year: 2021
  end-page: 921
  article-title: Characterization of asthma and risk factors for delayed SARS‐CoV‐2 clearance in adult COVID‐19 inpatients in Daegu
  publication-title: Allergy
– volume: 397
  start-page: 72
  year: 2021
  end-page: 74
  article-title: Oxford‐AstraZeneca COVID‐19 vaccine efficacy
  publication-title: Lancet
– volume: 382
  year: 2020
  article-title: Covid‐19 and health care's digital revolution
  publication-title: N Engl J Med
– volume: 11
  year: 2021
  article-title: Patients with suspected allergic reactions to COVID‐19 vaccines can be safely revaccinated after diagnostic work‐up
  publication-title: Clin Transl Allergy
– volume: 76
  start-page: 902
  year: 2021
  end-page: 905
  article-title: Severe asthma in adults does not significantly affect the outcome of COVID‐19 disease: results from the Italian Severe Asthma Registry
  publication-title: Allergy
– volume: 76
  start-page: 871
  year: 2021
  end-page: 874
  article-title: COVID‐19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: results from a multicenter Italian survey
  publication-title: Allergy
– volume: 76
  start-page: 735
  year: 2021
  end-page: 750
  article-title: Cabbage and fermented vegetables: from death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID‐19
  publication-title: Allergy
– volume: 75
  start-page: 2405
  year: 2020
  end-page: 2408
  article-title: Clinical characteristics of COVID‐19 patients combined with allergy
  publication-title: Allergy
– volume: 369
  start-page: 712
  year: 2020
  end-page: 717
  article-title: Type I and III interferons disrupt lung epithelial repair during recovery from viral infection
  publication-title: Science
– year: 2021
  article-title: COVID‐19 pandemic and allergen immunotherapy ‐ an EAACI survey
  publication-title: Allergy
– year: 2021
  article-title: Adding the variable of environmental complexity into the COVID‐19 pandemic equation
  publication-title: Allergy
– volume: 75
  start-page: 2703
  year: 2020
  end-page: 2704
  article-title: Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID‐19
  publication-title: Allergy
– volume: 76
  start-page: 648
  year: 2021
  end-page: 676
  article-title: COVID‐19 pandemic: practical considerations on the organization of an allergy clinic‐An EAACI/ARIA Position Paper
  publication-title: Allergy
– volume: 143
  start-page: 155
  year: 2019
  end-page: 172
  article-title: Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis
  publication-title: J Allergy Clin Immunol
– volume: 146
  start-page: 80
  year: 2020
  end-page: 88
  article-title: Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells
  publication-title: J Allergy Clin Immunol
– volume: 75
  start-page: 2399
  year: 2020
  end-page: 2402
  article-title: Managing ocular allergy in the time of COVID‐19
  publication-title: Allergy
– volume: 11
  year: 2020
  article-title: Could an unrelated live attenuated vaccine serve as a preventive measure to dampen septic inflammation associated with COVID‐19 infection?
  publication-title: mBio
– volume: 146
  start-page: 203
  year: 2020
  end-page: 206
  article-title: Association of respiratory allergy, asthma, and expression of the SARS‐CoV‐2 receptor ACE2
  publication-title: J Allergy Clin Immunol
– volume: 10
  year: 2020
  article-title: Is diet partly responsible for differences in COVID‐19 death rates between and within countries?
  publication-title: Clin Transl Allergy
– volume: 76
  start-page: 562
  year: 2021
  end-page: 564
  article-title: Eosinopenia is associated with greater severity in patients with coronavirus disease 2019
  publication-title: Allergy
– volume: 75
  start-page: 1546
  year: 2020
  end-page: 1554
  article-title: Handling of allergen immunotherapy in the COVID‐19 pandemic: an ARIA‐EAACI statement
  publication-title: Allergy
– year: 2021
  article-title: Allergenic components of the mRNA‐1273 vaccine for COVID‐19: possible involvement of polyethylene glycol and IgG‐mediated complement activation
  publication-title: Allergy
– volume: 385
  start-page: 239
  year: 2021
  end-page: 250
  article-title: Safety, immunogenicity, and efficacy of the BNT162b2 COVID‐19 vaccine in adolescents
  publication-title: N Engl J Med
– volume: 384
  start-page: 2273
  year: 2021
  end-page: 2282
  article-title: Preliminary findings of mRNA covid‐19 vaccine safety in pregnant persons
  publication-title: N Engl J Med
– volume: 383
  start-page: 2603
  year: 2020
  end-page: 2615
  article-title: Safety and efficacy of the BNT162b2 mRNA COVID‐19 vaccine
  publication-title: N Engl J Med
– volume: 76
  start-page: 966
  year: 2021
  end-page: 967
  article-title: Cabbage and COVID‐19
  publication-title: Allergy
– volume: 76
  start-page: 951
  year: 2021
  end-page: 952
  article-title: Comment on: Bilò MB, Pravettoni V, Mauro M, Bonadonna P. Treating venom allergy during COVID‐19 pandemic: management of venom allergen immunotherapy during the COVID‐19 outbreak in Spain
  publication-title: Allergy
– volume: 76
  start-page: 1765
  year: 2021
  end-page: 1775
  article-title: Childhood asthma outcomes during the COVID‐19 pandemic: findings from the PeARL multi‐national cohort
  publication-title: Allergy
– volume: 76
  start-page: 2904
  year: 2021
  end-page: 2907
  article-title: ACE2 downregulation in olfactory mucosa: eosinophilic rhinosinusitis as COVID‐19 protective factor?
  publication-title: Allergy
– volume: 70
  start-page: 910
  year: 2015
  end-page: 920
  article-title: Th2 cytokines impair innate immune responses to rhinovirus in respiratory epithelial cells
  publication-title: Allergy
– volume: 142
  start-page: 171
  year: 2018
  end-page: 177
  article-title: Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma
  publication-title: J Allergy Clin Immunol
– volume: 76
  start-page: 961
  year: 2021
  end-page: 962
  article-title: Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes from COVID‐19?
  publication-title: Allergy
– ident: e_1_2_8_49_1
  doi: 10.1016/j.jaip.2020.12.045
– ident: e_1_2_8_53_1
  doi: 10.1111/all.14455
– ident: e_1_2_8_7_1
  doi: 10.1111/all.14537
– ident: e_1_2_8_97_1
  doi: 10.1111/all.14793
– ident: e_1_2_8_123_1
  doi: 10.1001/jama.2020.8711
– ident: e_1_2_8_104_1
  doi: 10.1111/all.14767
– ident: e_1_2_8_32_1
  doi: 10.1186/s13601‐020‐00362‐7
– ident: e_1_2_8_128_1
  doi: 10.1111/all.14725
– ident: e_1_2_8_56_1
  doi: 10.1016/j.jmii.2020.03.005
– ident: e_1_2_8_108_1
  doi: 10.1111/all.14449
– ident: e_1_2_8_20_1
  doi: 10.1111/all.14589
– ident: e_1_2_8_16_1
  doi: 10.15585/mmwr.mm6915e3
– ident: e_1_2_8_105_1
  doi: 10.1128/mBio.00907‐20
– ident: e_1_2_8_74_1
  doi: 10.1111/all.14522
– ident: e_1_2_8_10_1
  doi: 10.1111/all.14609
– ident: e_1_2_8_101_1
  doi: 10.1016/j.jaci.2018.08.022
– ident: e_1_2_8_43_1
  doi: 10.1038/nri3831
– ident: e_1_2_8_72_1
  doi: 10.1001/jama.2020.15276
– ident: e_1_2_8_21_1
  doi: 10.1111/all.14675
– volume: 33
  start-page: 185
  year: 1984
  ident: e_1_2_8_135_1
  article-title: Systemic allergic reactions following immunization with human diploid cell rabies vaccine
  publication-title: MMWR Morb Mortal Wkly Rep
– ident: e_1_2_8_65_1
  doi: 10.1189/jlb.3RU0315‐099R
– ident: e_1_2_8_46_1
  doi: 10.1016/j.jaci.2020.05.004
– ident: e_1_2_8_119_1
  doi: 10.1056/NEJMoa2034577
– ident: e_1_2_8_25_1
  doi: 10.1111/all.14972
– ident: e_1_2_8_37_1
  doi: 10.1111/all.14569
– ident: e_1_2_8_137_1
  doi: 10.1111/all.14739
– ident: e_1_2_8_115_1
  doi: 10.1056/NEJMoa2107058
– ident: e_1_2_8_118_1
  doi: 10.1056/NEJMoa2027906
– ident: e_1_2_8_112_1
  doi: 10.1056/NEJMoa2101544
– ident: e_1_2_8_133_1
  doi: 10.1136/bcr.02.2012.5797
– ident: e_1_2_8_88_1
  doi: 10.1111/all.14629
– ident: e_1_2_8_116_1
  doi: 10.1016/s0140‐6736(20)32623‐4
– ident: e_1_2_8_40_1
  doi: 10.1111/all.14796
– ident: e_1_2_8_31_1
  doi: 10.1186/s13601‐020‐00323‐0
– ident: e_1_2_8_87_1
  doi: 10.1111/all.14697
– ident: e_1_2_8_12_1
  doi: 10.1016/j.anai.2020.07.029
– ident: e_1_2_8_117_1
  doi: 10.1056/NEJMoa2107456
– ident: e_1_2_8_121_1
  doi: 10.1111/all.14726
– ident: e_1_2_8_125_1
  doi: 10.1111/all.14711
– ident: e_1_2_8_11_1
  doi: 10.1016/j.jaci.2020.07.026
– ident: e_1_2_8_102_1
  doi: 10.1016/j.jaci.2017.11.051
– ident: e_1_2_8_38_1
  doi: 10.1111/all.14787
– ident: e_1_2_8_6_1
  doi: 10.1111/all.14420
– ident: e_1_2_8_93_1
  doi: 10.1111/all.14302
– ident: e_1_2_8_69_1
  doi: 10.1111/all.14462
– ident: e_1_2_8_114_1
  doi: 10.1056/NEJMoa2108891
– ident: e_1_2_8_131_1
  doi: 10.1007/s11882‐015‐0525‐1
– ident: e_1_2_8_29_1
  doi: 10.1111/all.14654
– ident: e_1_2_8_62_1
  doi: 10.1126/science.abc2061
– ident: e_1_2_8_124_1
  doi: 10.1016/s0140‐6736(21)00448‐7
– ident: e_1_2_8_34_1
  doi: 10.1111/all.14966
– ident: e_1_2_8_58_1
  doi: 10.1111/all.14353
– ident: e_1_2_8_67_1
  doi: 10.4049/jimmunol.148.7.2142
– ident: e_1_2_8_44_1
  doi: 10.1111/all.14728
– ident: e_1_2_8_41_1
  doi: 10.1111/all.14894
– ident: e_1_2_8_83_1
  doi: 10.1111/all.14596
– ident: e_1_2_8_63_1
  doi: 10.1093/infdis/jiab288
– ident: e_1_2_8_91_1
  doi: 10.1111/all.14439
– ident: e_1_2_8_36_1
  doi: 10.1016/s0140‐6736(20)32579‐4
– ident: e_1_2_8_120_1
  doi: 10.1001/jama.2021.0600
– ident: e_1_2_8_132_1
  doi: 10.1111/all.14761
– ident: e_1_2_8_35_1
  doi: 10.1111/all.14818
– ident: e_1_2_8_3_1
  doi: 10.1111/all.14238
– ident: e_1_2_8_90_1
  doi: 10.1111/all.14361
– ident: e_1_2_8_130_1
  doi: 10.1111/cea.12882
– ident: e_1_2_8_98_1
  doi: 10.1111/all.14473
– ident: e_1_2_8_106_1
  doi: 10.1111/all.14456
– ident: e_1_2_8_75_1
  doi: 10.1111/all.14687
– ident: e_1_2_8_54_1
  doi: 10.4049/jimmunol.1600787
– ident: e_1_2_8_5_1
  doi: 10.1111/all.14601
– ident: e_1_2_8_55_1
  doi: 10.1016/j.jaci.2020.04.021
– ident: e_1_2_8_59_1
  doi: 10.1126/science.abc6027
– ident: e_1_2_8_23_1
  doi: 10.1038/s41577‐021‐00516‐z
– ident: e_1_2_8_47_1
  doi: 10.1038/s41467‐020‐18781‐2
– ident: e_1_2_8_110_1
  doi: 10.1056/NEJMc2101951
– ident: e_1_2_8_111_1
  doi: 10.1056/NEJMoa2104983
– ident: e_1_2_8_81_1
  doi: 10.1111/all.14831
– ident: e_1_2_8_14_1
  doi: 10.1111/all.14289
– ident: e_1_2_8_17_1
  doi: 10.1101/2020.05.06.20092957
– ident: e_1_2_8_33_1
  doi: 10.1073/pnas.2019034118
– ident: e_1_2_8_18_1
  doi: 10.1111/all.14482
– ident: e_1_2_8_107_1
  doi: 10.1111/all.14516
– ident: e_1_2_8_4_1
  doi: 10.1111/all.14426
– ident: e_1_2_8_66_1
  doi: 10.1016/j.jaci.2008.08.028
– ident: e_1_2_8_19_1
  doi: 10.1016/j.jaci.2020.06.010
– ident: e_1_2_8_99_1
  doi: 10.1111/all.14336
– ident: e_1_2_8_113_1
  doi: 10.1056/NEJMoa2107659
– ident: e_1_2_8_24_1
  doi: 10.1111/all.14551
– ident: e_1_2_8_13_1
  doi: 10.1111/all.14593
– ident: e_1_2_8_64_1
  doi: 10.1016/j.chom.2016.01.007
– ident: e_1_2_8_129_1
  doi: 10.1111/all.14794
– ident: e_1_2_8_48_1
  doi: 10.1111/all.14904
– ident: e_1_2_8_79_1
  doi: 10.1111/all.14591
– ident: e_1_2_8_96_1
  doi: 10.1111/all.14567
– ident: e_1_2_8_138_1
  doi: 10.1002/clt2.12044
– ident: e_1_2_8_94_1
  doi: 10.1111/all.14453
– ident: e_1_2_8_42_1
  doi: 10.1111/all.14873
– ident: e_1_2_8_136_1
  doi: 10.1016/j.jinf.2004.05.018
– ident: e_1_2_8_134_1
  doi: 10.1111/all.14774
– ident: e_1_2_8_76_1
  doi: 10.1056/NEJMp2005835
– ident: e_1_2_8_50_1
  doi: 10.1016/j.eclinm.2020.100375
– ident: e_1_2_8_45_1
  doi: 10.1016/j.jaci.2020.04.009
– ident: e_1_2_8_109_1
  doi: 10.1111/all.14407
– ident: e_1_2_8_95_1
  doi: 10.1111/all.14876
– ident: e_1_2_8_2_1
  doi: 10.1111/all.14348
– ident: e_1_2_8_103_1
  doi: 10.1111/all.14534
– ident: e_1_2_8_8_1
  doi: 10.1111/all.14558
– ident: e_1_2_8_139_1
  doi: 10.1111/all.14838
– ident: e_1_2_8_22_1
  doi: 10.1016/j.jaci.2020.09.017
– ident: e_1_2_8_100_1
  doi: 10.1016/j.jaci.2004.11.053
– ident: e_1_2_8_39_1
  doi: 10.1001/jama.2020.21231
– ident: e_1_2_8_57_1
  doi: 10.4049/jimmunol.1102299
– ident: e_1_2_8_78_1
  doi: 10.1016/s0140‐6736(20)30818‐7
– ident: e_1_2_8_71_1
  doi: 10.1111/all.14498
– ident: e_1_2_8_84_1
  doi: 10.1111/all.14467
– ident: e_1_2_8_28_1
  doi: 10.1111/all.14653
– ident: e_1_2_8_51_1
  doi: 10.1164/rccm.202003‐0543OC
– ident: e_1_2_8_73_1
  doi: 10.1111/all.14429
– ident: e_1_2_8_89_1
  doi: 10.1111/all.13786
– ident: e_1_2_8_86_1
  doi: 10.1016/s0140‐6736(20)32317‐5
– ident: e_1_2_8_122_1
  doi: 10.1111/all.14840
– ident: e_1_2_8_127_1
  doi: 10.1111/all.14722
– ident: e_1_2_8_68_1
  doi: 10.1111/all.12627
– ident: e_1_2_8_30_1
  doi: 10.1111/all.14549
– ident: e_1_2_8_126_1
  doi: 10.1111/all.14734
– ident: e_1_2_8_77_1
  doi: 10.1056/NEJMp2003539
– ident: e_1_2_8_15_1
  doi: 10.1111/all.14472
– ident: e_1_2_8_60_1
  doi: 10.1038/s41586‐021‐03234‐7
– ident: e_1_2_8_80_1
  doi: 10.1016/j.jaip.2020.03.012
– ident: e_1_2_8_52_1
  doi: 10.1111/all.14708
– ident: e_1_2_8_70_1
  doi: 10.1111/all.14434
– ident: e_1_2_8_85_1
  doi: 10.1001/jama.2020.8391
– ident: e_1_2_8_27_1
  doi: 10.1126/science.abb4218
– ident: e_1_2_8_26_1
  doi: 10.1016/j.jaci.2020.08.008
– ident: e_1_2_8_61_1
  doi: 10.1016/s1473‐3099(20)30270‐x
– ident: e_1_2_8_9_1
  doi: 10.1111/all.14532
– ident: e_1_2_8_82_1
  doi: 10.1093/infdis/jiaa189
– ident: e_1_2_8_92_1
  doi: 10.1111/all.14471
SSID ssj0000581000
Score 2.2203698
SecondaryResourceType review_article
Snippet Background Since the first reports of coronavirus disease 2019 (COVID‐19) in Wuhan, China, in December 2019, there have been 198 million confirmed cases...
Since the first reports of coronavirus disease 2019 (COVID-19) in Wuhan, China, in December 2019, there have been 198 million confirmed cases worldwide as of...
BackgroundSince the first reports of coronavirus disease 2019 (COVID‐19) in Wuhan, China, in December 2019, there have been 198 million confirmed cases...
Abstract Background Since the first reports of coronavirus disease 2019 (COVID‐19) in Wuhan, China, in December 2019, there have been 198 million confirmed...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage e12065
SubjectTerms Allergies
allergy
Asthma
Biomarkers
Clinical outcomes
Coronaviruses
COVID-19
Cytokines
Disease
Gene expression
Genotype & phenotype
Hay fever
Immunotherapy
Impfung
Infections
Inflammation
mechanism
Mechanismen
Medical supplies
Mortality
Pandemics
Proteins
Review
Rhinitis
Schlüsselwörter: Allergie
Severe acute respiratory syndrome coronavirus 2
Therapie
treatment
vaccination
Viral infections
Viruses
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwEB7BFqRe-IeGtsgILiCldRzbcU6oXVqBVC1VVareIsc_sFKVlM0WiRuPwDPyJLUdb9oVVS_klDijaKzxjL-MR98AvCUFFtSWPFW1YimVxKZSyTzFnlyO1JnmgdTn5KCYTMTpaXkYE25dLKtcxMQQqHWrfI58mxQZc1CFY_rh_Efqu0b509XYQuMurHimMjqCld29yeHRkGXBTPgE9sBLSrbV2ZxsZQT73eTaThQI-29Cmf8WS14HsWEX2n_4v_o_ggcRf6KdfsE8hjumeQL3-46Uv57CkYORTgMUSwM6JBuN9FVhUYemDRp_Ofn88e_vP1npnxyCRL7g3UV51Frke7PMXDhF8einewZf9_eOx5_S2HYhVcx5cKqF4UxJYrjkhthClEZR6WCXltSNMOfRpWdVUwYrmquizoTlhhquMVW5IflzGDVtY9YAUSylYJoUhEmq3KdUoEQrc_fXI60hCbxbmKBSkZPct8Y4q3o2ZVJ5c1XBXAm8GWTPeyaOG6V2vSUHCc-eHQba2bcqOmMlTJ1L6-CBxJbWMpe1sFaT3DowZVlJE9hY2LCKLt1VVwZM4PXw2jmjP2GRjWkvnEyQYO5K4EW_bAZNcn9C6eBcAsXSglpSdflNM_0eCL8Fp5zjMoH3YendMv1qfHBMwt3L2-ewDqvEV-eEarkNGM1nF2YT7qmf82k3exXd6BKWmSfF
  priority: 102
  providerName: ProQuest
– databaseName: Wiley-Blackwell Open Access Titles
  dbid: 24P
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB6VAlIvvB-BgozgAlJax684EhdYqECqSoVK1ZvlODasVGWrzRaJGz-B38gvYexks6yokBA5JfYk8WPG_mJPvgF4xkqqRahU7monc2FZyK2zPKeRXI7VRaMSqc_xfnlwoE9OqsMNeLn8F6bnhxgX3KJlpPE6Gritu90Vaag7XbCdguEUegkuFwXXMXADE4fjCguVOi5ex-hyiFvyEmerkZ-U7a5uX5uREnH_RWjzT6fJ38Fsmo32rv9fPW7AtQGFkle92tyEDd_egqt9XMpvt-Ejgkl8PxkcBDpi24Y0K_eijkxbMvlw_P7Nz-8_iipeIY4k0e0dx3oyCyRGaJnjoEqGDaDuDnzae3s0eZcPwRdyJ9GO80Z7JZ1lXlnlWSh15Z2wCL4aKzBFol1XkVvNeeoEd2Vd6KC88KqhwnHP-F3YbGetvw9EUGu1bFjJpBUOH-USMVrF8dvHBs8yeL7sAOMGZvIYIOPU9JzKzMQ2MqmNMng6yp71fBwXSr2O_ThKRA7tlDCbfzaDSRrta24DggRLg6gtt7UOoWE8IKQKshIZbC-1wAyG3RlWFhIRs6KY_WTMRpOM-yy29bNzlEkSEo8M7vVKM5aEx31KBHUZlGvqtFbU9Zx2-iXRfmsllKJVBi-SOv2l-mayf8TS2YN_EX4IWyx67CQPum3YXMzP_SO44r4upt38cTKuX6uNJjM
  priority: 102
  providerName: Wiley-Blackwell
Title Recent advances and developments in COVID‐19 in the context of allergic diseases
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fclt2.12065
https://www.ncbi.nlm.nih.gov/pubmed/34582102
https://www.proquest.com/docview/2715774604
https://www.proquest.com/docview/2577465555
https://pubmed.ncbi.nlm.nih.gov/PMC8646609
https://doaj.org/article/8eb3afceea0f4ba3ab8ffd23f317f594
Volume 11
WOSCitedRecordID wos000700512800005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVADU
  databaseName: BioMed Central
  customDbUrl:
  eissn: 2045-7022
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000581000
  issn: 2045-7022
  databaseCode: RBZ
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.biomedcentral.com/search/
  providerName: BioMedCentral
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2045-7022
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000581000
  issn: 2045-7022
  databaseCode: DOA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2045-7022
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000581000
  issn: 2045-7022
  databaseCode: M~E
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 2045-7022
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000581000
  issn: 2045-7022
  databaseCode: 7X7
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 2045-7022
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000581000
  issn: 2045-7022
  databaseCode: BENPR
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Publicly Available Content Database
  customDbUrl:
  eissn: 2045-7022
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000581000
  issn: 2045-7022
  databaseCode: PIMPY
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVWIB
  databaseName: Wiley Online Library
  customDbUrl:
  eissn: 2045-7022
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000581000
  issn: 2045-7022
  databaseCode: WIN
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://onlinelibrary.wiley.com
  providerName: Wiley-Blackwell
– providerCode: PRVWIB
  databaseName: Wiley Online Library Open Access
  customDbUrl:
  eissn: 2045-7022
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000581000
  issn: 2045-7022
  databaseCode: 24P
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  providerName: Wiley-Blackwell
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwEB5BAakXxG8JlJURXEAKdRzHdo50acVKZYmqUpZT5Di2WKnKVpstEjcegWfkSRg7adgVFVzIIYrjkeWMZ-zP8egbgBdMUsVdLmJTmSzmmrlYG53G1JPLsSqpRSD1OT2S06mazfJiLdWXjwnr6IE7xe0p3O1ph1O5po5XOtWVcq5mqcOFz2V5YAJF1LO2mepYvZX_cT3wkbI9c7ZirxNG_SqytgIFov6r0OWfQZLr4DWsPod34HYPG8mbrrt34Zpt7sGtLpHkt_twjOgPGyD9iX5LdFOT-nc8UEvmDRl_OJ28_fn9R5L7EgI_4uPUcXImC0d8SpUlzoKkP7FpH8DHw4OT8bu4z5YQmwwdL66VFZnRzAotLHNS5dZwjWip1hzfZOiIuSdDM5YanhpZJcoJy62oKTepZelD2GoWjX0EhFOtVVYzyTLNDTZlApNZnuJmRTvLInh5qcHS9FTiPqPFWdmRILPSa7sM2o7g-SB73hFoXCm17wdikPCk1-EFmkLZm0L5L1OIYPdyGMveE9uSySRDiCsoVj8bqtGH_MGIbuziAmWCRIZXBDvdqA89Sf3BIqKwCOSGPWx0dbOmmX8JPN1KcCFoHsGrYDl_-fxyfHTCwtPj_6GIJ7DNfOhNCIXbha3V8sI-hZvm62reLkdwnfEC73Imw12N4Mb-wbQ4HgUfwlIxeV98xtKnyfQX18Ahrw
linkProvider Directory of Open Access Journals
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtQwEB5VWxBc-P8JFDACDiCFJo7jOAeEYEvVVbfLCi1VOQXHsWGlKimbLag3HoEn4aF4EsZONu2KqrceyCk_oyhOPs98tiffADylSSCYSbmvchX7TFLjSyUjP7DicjQPC-5EfXaHyWgk9vbS8Qr8XvwLY9MqFz7ROeqiUnaOfJ0mYYxUhQfs9cE331aNsqurixIaDSy29dEPHLLVrwYb-H2fUbr5btLf8tuqAr6KEaB-ITSPlaSaS66pSUSqFZPIKgrJ8EyMgE2taJjSgWKRSvJQGK6Z5kXAVKSt0AG6_FWG9xI9WB0PdsafulmdIBZ2wrzTQaXran9OX4Y0sNHrRORzBQJOY7X_JmeeJM0u6m1e_d_e1zW40vJr8qbpENdhRZc34GJTcfPoJnxAmowtJm3qQ01kWZDiOHGqJtOS9N_vDjb-_PwVpvYIGTKxCf0YxUhliK09M8NwQdqlrfoWfDyXBt2GXlmV-i4QFkgp4oImNJZM4a2Uk3xLIxzVSaOpB88XnzxTrea6Lf2xnzVq0TSz8MgcPDx40tkeNEojp1q9tcjpLKw6uDtRzb5krbPJhM4jaZD-yMCwXEYyF8YUNDJIFk2cMg_WFpjJWpdVZ8eA8eBxdxmdjV1BkqWuDtHGWcS4eXCngWn3JJFdgUW66kGyBOClR12-Uk6_OkFzwRnnQerBCwf1M5qf9YcT6vbund2GR3Bpa7IzzIaD0fZ9uExtJpLLDFyD3nx2qB_ABfV9Pq1nD9suTODzefeCv1ruhQY
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtQwEB5VLSAu_P8EChgBB5DCJo7jOAeEYJcVqy7LCpWqnILj2LBSlZTNFtQbj8Dz8Dg8CWMnm3ZF1VsP5JSfUZRJPo8_25NvAB7TJBDMpNxXuYp9JqnxpZKRH1hxOZqHBXeiPjvjZDIRu7vpdA1-L_-FsWmVy5joAnVRKTtH3qNJGCNV4QHrmTYtYjoYvtz_5tsKUnaldVlOo4HIlj78gcO3-sVogN_6CaXDN9v9t35bYcBXMYLVL4TmsZJUc8k1NYlItWISGUYhGZ6JEbypFRBTOlAsUkkeCsM107wImIq0FT3A8L-BlJxhG9uYjt5NP3UzPEEs7OR5p4lKe2pvQZ-HNLA92bFe0BULOInh_puoeZxAux5wePl_fndX4FLLu8mrpqFchTVdXoPzTSXOw-vwAekzek_alIiayLIgxVFCVU1mJem_3xkN_vz8Fab2CJkzsYn-6CapDLE1aebYjZB2yau-AR_PxKGbsF5Wpb4NhAVSirigCY0lU3gr5aTg0ghHe9Jo6sHT5efPVKvFbkuC7GWNijTNLFQyBxUPHnW2-40CyYlWry2KOgurGu5OVPMvWRuEMqHzSBqkRTIwLJeRzIUxBY0MkkgTp8yDzSV-sjaU1dkReDx42F3GIGRXlmSpqwO0cRYxbh7caiDbPUlkV2aRxnqQrIB55VFXr5Szr07oXHDGeZB68MzB_hT3s_54m7q9O6f78AAuIPSz8WiydRcuUpug5BIGN2F9MT_Q9-Cc-r6Y1fP7bWsm8PmsG8FfZJqNxg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Recent+advances+and+developments+in+COVID%E2%80%9019+in+the+context+of+allergic+diseases&rft.jtitle=Clinical+and+translational+allergy&rft.au=Ding%2C+Mei&rft.au=Dong%2C+Xiang&rft.au=Sun%2C+Yuan%E2%80%90li&rft.au=Sokolowska%2C+Milena&rft.date=2021-09-01&rft.pub=John+Wiley+and+Sons+Inc&rft.eissn=2045-7022&rft.volume=11&rft.issue=7&rft_id=info:doi/10.1002%2Fclt2.12065&rft_id=info%3Apmid%2F34582102&rft.externalDocID=PMC8646609
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-7022&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-7022&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-7022&client=summon